期刊文献+

缬沙坦对人脐动脉平滑肌细胞PAPP-A、IGF-1表达的影响

Influence of valsartan on PAPP-A,IGF-1 gene expression in HUVSMC
下载PDF
导出
摘要 目的:探讨缬沙坦对人脐动脉平滑肌细胞PAPP-A、IGF-1表达的影响。方法:分别在10-5mol/L的Ox-LDL的基础上,给予AngII以及AngII、缬沙坦混合培养人脐动脉平滑肌细胞,以普通培养基培养为对照,应用ELISA及RT-PCR的方法分别检测上清液及细胞内PAPP-A、IGF-1的表达量。结果:AngII组PAPP-A与IGF-1的表达量均显著高于对照组、Ox-LDL及缬沙坦组(P<0.01),缬沙坦组IGF-1的表达量及PAPP-ARNA的表达量与Ox-LDL组无明显差异(P>0.05),而缬沙坦组细胞外PAPP-A分泌量则与其它各组均差异明显(P<0.01)。结论:AngII可促进人脐动脉平滑肌细胞PAPP-A和IGF-1的表达,缬沙坦可以抑制AngII的这种作用,缬沙坦对AngII作用下PAPP-A细胞内RNA表达的抑制较细胞外蛋白分泌的抑制明显。 Objective : To study the effect of Valsartan on the expressions of the PAPP-A, IGF-1 in human umbilical vein smooth muscle cell. Methods: Under the condition of ox-LDL of 10^-5 moL/L, HUVSMC is cultured with Ang Ⅱ , and with the combination of Aug Ⅱ and Valsartau. Compared with normal cultivation without ox-LDL, the expressions of PAPP-A, IGF-1 are assayed using RT-PCR and ELISA. Results: The expressions of PAPP-A and IGF-1 that Ang Ⅱ induces are significantly higher than those in other groups. The Valsartan group makes no significant differences compared with the ox-LDL group in the mRNA expressions of PAPP-A and IGF-1. The ex-cell expression of PAPP-A that Valsartan induces has significant difference compared with ones in other groups. Conclusion: Aug Ⅱ induces the expressions of PAPP-A, IGF-1 while Valsartan can deregulate the role that Ang Ⅱ plays, especially through the ex-cell pathway.
出处 《军医进修学院学报》 CAS 2009年第2期180-182,共3页 Academic Journal of Pla Postgraduate Medical School
基金 全军医药卫生‘十五’计划课题(04LX048) 全军医药卫生‘十一五’计划科技攻关课题(06G144)
关键词 急性冠状动脉综合征 血管紧张素Ⅱ 妊娠相关蛋白-A 胰岛素样生长因子Ⅰ 缬沙坦 acute coronary, syndrome AngⅡ PAPP-A IGF-1 valsartan
  • 相关文献

参考文献7

  • 1Bauriedel G, Windstetter U, DeMaio SJ Jr, et al. Migratory activity of human smooth muscle cells cultivated from coronary and peripheral primary and restenotic lesions removed by percutaneous atherectomy [ J ]. Circulation, 1992, 85 (2) :554-564.
  • 2Qiao JH, Fishbein MC. The severity of coronary atherosclerosis at sites of plaque rupture with occlusive thrombosis [J]. J Am Coil Cardiol, 2001, 37 : 1277-1283.
  • 3刘晓红.非ST抬高性急性冠脉综合征患者血清MMP-9及TIMP-1与AngⅡ浓度改变意义[J].实用诊断与治疗杂志,2007,21(10):729-731. 被引量:12
  • 4Hanefeld, AbtetShauser CJ. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension[ J]. Int Med Res, 2001, 29(4) :270.
  • 5de las Heras N, Aragoncillo P, Maeso R, et al. AT( 1 ) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits [J]. Hypertension, 1999, 34 ( part 2 ) : 969.
  • 6吕吉元 杨丽峰 贾永平.缬沙坦对PCI术后内皮功能不全的干预研究.中华心血管病杂志,2004,32(10):346-346.
  • 7Peters S, Gotting B, Trummel M, et al. Valsartan for prevention of restenosis ariel stenting of type B2/C Lesions:the Val-PREST trial[J]. J Invasive cardiol, 2001, 13(2):93-97.

二级参考文献11

  • 1曹国良,乔永芳,刘新兵,俞建华.辛伐他汀早期干预对非ST抬高型急性冠脉综合征细胞因子水平的影响[J].实用诊断与治疗杂志,2006,20(7):478-480. 被引量:40
  • 2曹国良,乔永芳,戴蓉芳,刘新兵,俞建华.老年冠心病支架置入术前后血清IL-6,TNF-α水平改变的临床意义[J].实用诊断与治疗杂志,2006,20(8):565-567. 被引量:26
  • 3Ramin R, Eric J T. Strategies to achieve coronary arterial plague stabilization[J]. Cardiovasc Res,1999,41(2):402-417.
  • 4Ishikawa Y, Asuwa N, Ishii T, et al. Vascular remodeling by hermodynamic factors[J].Virchowa Arch,2000,437(2):138-148.
  • 5胡大,马长生.心脏病学实践2003,新进展与临床案例[M].北京:人民卫生出版社,2003,23-34.
  • 6Mclennan S, Fisher E, Martell S, et al. Effects of glucose on matrix metalloproteinase and plasm in activities in mesangial cells: possible role in diabetic nephropathy[J]. Kidney Int, 2000, 58 (Suppl 77):S 81-87.
  • 7Nomoto K, Oguchi S, Walanabe I, et al. Involvement of inflammation in acute coronary syndromes assessed by levels of high sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1[J]. J Cardiol, 2003,42(5):201-206.
  • 8Schonbec K U, Mach F, Sukhova G K, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: A role for CD40 signaling in plaque rupture[J]? Circ Res,1997,81(3):448-454.
  • 9Creemers E E, Cleutjens J P, Smits J F, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure [J]? Circ Res, 2001,89(2):201-210.
  • 10Yoon Y W, Kwon H M, Hwang K C, et al. Upstream regulation of matrix metalloproteinase by EMMPRIN: extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque [J]. Atheroselerosis, 2005,180(1):37-44.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部